Author

Stuart Lacey 1

1 Roche Produc

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO ANTI-TUMOR NECROSIS FACTOR AGENT: THE RANDOMIZED, PHASE 3 HICKORY TRIAL

Laurent Peyrin-Biroulet, Ailsa L Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward V Loftus Jr, Elham Ostad-Saffari, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William Sandborn

ETROLIZUMAB COMPARED WITH ADALIMUMAB OR PLACEBO AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED, PHASE 3 HIBISCUS I & II TRIALS

Iris Dotan, Julian Panés, Aaron Duvall, Yoram Bouhnik, Graham Radford-Smith, Peter D.R. Higgins, Daniel S. Mishkin, Pablo Arrisi, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, David T. Rubin

Evaluation of Paired and Separated Endoscopic Reads at Baseline and Week 14 in the Exploratory BERGAMOT Induction Cohort

Daniel S. Mishkin, Stefan Schreiber, Marco Daperno, Young Oh, Fez Hussain, Azra Hassanali, Stuart Lacey, Regan Li, Walter Reinisch

Item 1 - 3 / 3
1